(Q33887470)

English

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance (English)

1 reference

Europe PubMed Central

29 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

2

object named as

Frits van Rhee

0 references

10

object named as

Bart Barlogie

1 reference

Europe PubMed Central

29 July 2017

8

object named as

Sarah Waheed

1 reference

Europe PubMed Central

29 July 2017

6

object named as

Antje Hoering

1 reference

Europe PubMed Central

29 July 2017

4

object named as

Elias Anaissie

1 reference

Europe PubMed Central

29 July 2017

author name string

Bijay Nair

1

1 reference

Europe PubMed Central

29 July 2017

John D Shaughnessy

3

1 reference

Europe PubMed Central

29 July 2017

Jackie Szymonifka

5

1 reference

Europe PubMed Central

29 July 2017

Yazan Alsayed

7

1 reference

Europe PubMed Central

29 July 2017

John Crowley

9

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

2 February 2010

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

115

1 reference

Europe PubMed Central

29 July 2017

4168-4173

1 reference

Europe PubMed Central

29 July 2017

21

1 reference

Europe PubMed Central

29 July 2017

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

The molecular classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

5 July 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

29 October 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2879104

29 October 2018

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-11-255620

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33887470&oldid=1626086987"